-+ 0.00%
-+ 0.00%
-+ 0.00%

Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Lowers Price Target to $15

Benzinga·04/06/2026 12:43:07
Listen to the news
Benchmark analyst Bruce D. Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and lowers the price target from $21 to $15.